H.C. Wainwright Maintains Buy on Akebia Therapeutics, Lowers Price Target to $16

H.C. Wainwright maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $17 to $16.

Benzinga · 11/18/2019 14:54

H.C. Wainwright maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $17 to $16.